The socioeconomic impact of multiple sclerosis in France: Results from the PETALS study
A Bouleau, C Dulong, CA Schwerer… - Multiple Sclerosis …, 2022 - journals.sagepub.com
Background Multiple sclerosis (MS) places a considerable financial burden on the society.
However, data quantifying the contemporary cost burden in France are lacking. Objective …
However, data quantifying the contemporary cost burden in France are lacking. Objective …
New insights into the burden and costs of multiple sclerosis in Europe: Results for France
C Lebrun-Frenay, G Kobelt, J Berg… - Multiple Sclerosis …, 2017 - journals.sagepub.com
Introduction: To estimate the value of interventions in multiple sclerosis (MS)–where lifetime
costs and outcomes cannot be observed–outcome data have to be combined with costs …
costs and outcomes cannot be observed–outcome data have to be combined with costs …
Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims
D Bruno, D Marc, P Ouarda, S Dominique… - Multiple sclerosis and …, 2019 - Elsevier
Background Estimating direct healthcare costs of patients with multiple sclerosis (MS) and
identifying risk factors of high costs including relapse are important drivers of public health …
identifying risk factors of high costs including relapse are important drivers of public health …
Economic burden of multiple sclerosis in Slovakia—from 2015 to 2020
R Babela, J Dugas - BMC Health Services Research, 2022 - Springer
Background Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous
system, commonly diagnosed during young adulthood. The proportion of direct and indirect …
system, commonly diagnosed during young adulthood. The proportion of direct and indirect …
Cost of multiple sclerosis in France
A Fromont, MN Lehanneur, F Rollot, A Weill… - Revue …, 2014 - europepmc.org
Multiple sclerosis (MS) is one of the 30 chronic conditions specifically listed by the French
healthcare system as a long-term disease (affections de longue durée [ALD]) for which the …
healthcare system as a long-term disease (affections de longue durée [ALD]) for which the …
New insights into the burden and costs of multiple sclerosis in Europe: results for Germany
P Flachenecker, G Kobelt, J Berg… - Multiple Sclerosis …, 2017 - journals.sagepub.com
Introduction: To estimate the value of interventions in multiple sclerosis (MS)–where lifetime
costs and outcomes cannot be observed–outcome data have to be combined with costs …
costs and outcomes cannot be observed–outcome data have to be combined with costs …
New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium
B Dubois, G Kobelt, J Berg, D Capsa… - Multiple Sclerosis …, 2017 - journals.sagepub.com
Introduction: In order to estimate the value of interventions in multiple sclerosis (MS)–where
lifetime costs and outcomes cannot be observed–outcome data have to be combined with …
lifetime costs and outcomes cannot be observed–outcome data have to be combined with …
New insights into the burden and costs of multiple sclerosis in Europe: results for Italy
M Battaglia, G Kobelt, M Ponzio, J Berg… - Multiple Sclerosis …, 2017 - journals.sagepub.com
Introduction: In order to estimate the value of interventions in multiple sclerosis (MS)–where
lifetime costs and outcomes cannot be observed–outcome data have to be combined with …
lifetime costs and outcomes cannot be observed–outcome data have to be combined with …
Comparing costs of illness of multiple sclerosis in three different years: a population-based study
H Gyllensten, M Wiberg… - Multiple Sclerosis …, 2018 - journals.sagepub.com
Background: Little is known about changes in the costs of illness (COI) among multiple
sclerosis (MS) patients during recent years. Objectives: To compare the COI among MS …
sclerosis (MS) patients during recent years. Objectives: To compare the COI among MS …
New insights into the burden and costs of multiple sclerosis in Europe: results for Spain
C Oreja-Guevara, G Kobelt, J Berg… - Multiple Sclerosis …, 2017 - journals.sagepub.com
Introduction: In order to estimate the value of interventions in multiple sclerosis (MS) where
lifetime costs and outcomes cannot be observed, outcome data have to be combined with …
lifetime costs and outcomes cannot be observed, outcome data have to be combined with …